1. Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer;Agarwal,2017
2. HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer;Almassi,2018
3. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer;Alyamani,2018
4. Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk;Amrousy,2022
5. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven;Attard,2008